WEKO3
アイテム
{"_buckets": {"deposit": "7a69b587-24ed-4fb6-b124-57be32c0662e"}, "_deposit": {"id": "2001273", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2001273"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:02001273", "sets": []}, "author_link": [], "control_number": "2001273", "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-03-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "16", "bibliographicVolumeNumber": "9", "bibliographic_titles": [{"bibliographic_title": "Journal of personalized medicine"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Duchenne and Becker muscular dystrophy (DMD/BMD) are X-linked muscle disorders caused by mutations of the DMD gene, which encodes the subsarcolemmal protein dystrophin. In DMD, dystrophin is not expressed due to a disruption in the reading frame of the DMD gene, resulting in a severe phenotype. Becker muscular dystrophy exhibits a milder phenotype, having mutations that maintain the reading frame and allow for the production of truncated dystrophin. To date, various therapeutic approaches for DMD have been extensively developed. However, the pathomechanism is quite complex despite it being a single gene disorder, and dystrophin is expressed not only in a large amount of skeletal muscle but also in cardiac, vascular, intestinal smooth muscle, and nervous system tissue. Thus, the most appropriate therapy would be complementation or restoration of dystrophin expression, such as gene therapy using viral vectors, readthrough therapy, or exon skipping therapy. Among them, exon skipping therapy with antisense oligonucleotides can restore the reading frame and yield the conversion of a severe phenotype to one that is mild. In this paper, I present the significance of molecular diagnosis and the development of mutation-based therapeutic strategies to complement or restore dystrophin expression.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of personalized medicine 9(1) : 16-(2019)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "中村, 昭則", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.uaTUHhkh.html"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "30836656"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/30836656/", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.3390/jpm9010016"}], "subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3390/jpm9010016", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)."}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2075-4426", "subitem_source_identifier_type": "EISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2075-4426", "subitem_source_identifier_type": "EISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Akinori", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2023-01-20"}], "download_preview_message": "", "file_order": 0, "filename": "18H02577_1.pdf", "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_0", "mimetype": "application/pdf", "size": 0, "url": {"label": "18H02577_1.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/2001273/files/18H02577_1.pdf"}, "version_id": "f381c563-f8af-4b7d-9880-cbdebdc49e78"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Duchenne/Becker muscular dystrophy (DMD/BMD)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "DMD gene", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dystrophin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "molecular diagnosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "DMD model animal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gene therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "readthrough therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "exon skipping therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "antisense oligonucleotide", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["462"], "permalink_uri": "http://hdl.handle.net/10091/0002001273", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2023-01-20"}, "publish_date": "2023-01-20", "publish_status": "0", "recid": "2001273", "relation": {}, "relation_version_is_last": true, "title": ["Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy"], "weko_shared_id": -1}
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
http://hdl.handle.net/10091/0002001273
http://hdl.handle.net/10091/0002001273360ddf86-84af-453b-b44f-b180d37e7561
名前 / ファイル | ライセンス | アクション |
---|---|---|
18H02577_1.pdf
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||||
---|---|---|---|---|---|---|---|---|
公開日 | 2023-01-20 | |||||||
タイトル | ||||||||
言語 | en | |||||||
タイトル | Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy | |||||||
言語 | ||||||||
言語 | eng | |||||||
DOI | ||||||||
関連タイプ | isIdenticalTo | |||||||
識別子タイプ | DOI | |||||||
関連識別子 | https://doi.org/10.3390/jpm9010016 | |||||||
関連名称 | 10.3390/jpm9010016 | |||||||
キーワード | ||||||||
主題 | Duchenne/Becker muscular dystrophy (DMD/BMD), DMD gene, dystrophin, molecular diagnosis, DMD model animal, gene therapy, readthrough therapy, exon skipping therapy, antisense oligonucleotide | |||||||
資源タイプ | ||||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||||
タイプ | journal article | |||||||
著者 |
Nakamura, Akinori
× Nakamura, Akinori
|
|||||||
信州大学研究者総覧へのリンク | ||||||||
氏名 | 中村, 昭則 | |||||||
URL | https://soar-rd.shinshu-u.ac.jp/profile/ja.uaTUHhkh.html | |||||||
出版者 | ||||||||
出版者 | MDPI | |||||||
引用 | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | Journal of personalized medicine 9(1) : 16-(2019) | |||||||
書誌情報 |
Journal of personalized medicine 巻 9, 号 1, p. 16, 発行日 2019-03-04 |
|||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Duchenne and Becker muscular dystrophy (DMD/BMD) are X-linked muscle disorders caused by mutations of the DMD gene, which encodes the subsarcolemmal protein dystrophin. In DMD, dystrophin is not expressed due to a disruption in the reading frame of the DMD gene, resulting in a severe phenotype. Becker muscular dystrophy exhibits a milder phenotype, having mutations that maintain the reading frame and allow for the production of truncated dystrophin. To date, various therapeutic approaches for DMD have been extensively developed. However, the pathomechanism is quite complex despite it being a single gene disorder, and dystrophin is expressed not only in a large amount of skeletal muscle but also in cardiac, vascular, intestinal smooth muscle, and nervous system tissue. Thus, the most appropriate therapy would be complementation or restoration of dystrophin expression, such as gene therapy using viral vectors, readthrough therapy, or exon skipping therapy. Among them, exon skipping therapy with antisense oligonucleotides can restore the reading frame and yield the conversion of a severe phenotype to one that is mild. In this paper, I present the significance of molecular diagnosis and the development of mutation-based therapeutic strategies to complement or restore dystrophin expression. | |||||||
資源タイプ(コンテンツの種類) | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | Article | |||||||
ISSN | ||||||||
収録物識別子タイプ | EISSN | |||||||
収録物識別子 | 2075-4426 | |||||||
PubMed | ||||||||
識別子タイプ | PMID | |||||||
関連識別子 | https://pubmed.ncbi.nlm.nih.gov/30836656/ | |||||||
関連名称 | 30836656 | |||||||
権利 | ||||||||
権利情報 | © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |||||||
出版タイプ | ||||||||
出版タイプ | VoR | |||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |